Microsoft word - dawes cv 12-09-08.doc

CURRICULUM VITAE
Michael A. Dawes, M.D.
GENERAL INFORMATION
PERSONAL DATA:
Date of Preparation: 12-09-08
Medical School Address: University of Texas Health Science Center at San
Main Office:
University Plaza Building, 7526 Louis Pasteur Drive, San Be Well Center Address
Be Well Center-UTHSCSA 7526 Louis Pasteur Drive Phone Number:
Fax Number:
Email Address:
EDUCATION:
Degree Discipline
Institution/Location
University of North Carolina, Chapel Hill, University of North Carolina, Chapel Hill, TRAINING:
Internship
Discipline
Institution/Location
Post Doctoral Fellowships
Discipline
Institution/Location
7/6/1998 – 7/5/2000 Addiction Psychiatry 07/1/1994-6/30/1997 Early-onset substance University of Pittsburgh Medical Center, use disorders (Research Pittsburgh, PA Fellowship) Residency
Discipline
Institution/Location
7/1/1992 – 6/30/1994 Child and Adolescent Adolescent Psychiatry Program, Boston, MA 7/1/1987 – 6/30/1990 Administrative Psychiatry Medical College of Georgia, Augusta, ACADEMIC APPOINTMENTS:
University of Texas Health Science Center Department of Pschiatry, San Antonio, TX Details: Division of Alcohol and Drug Addiction
Psychiatry and Behavioral Medicine, Winston-Salem, NC University of Texas Health Science Center, Department of Psychiatry, San Antonio, TX Details: Division of Alcohol and Drug Addiction
University of Texas Health Science Center, Department of Psychiatry, San Antonio, TX Details: Division of Child and Adolescent Psychiatry
Western Psychiatric Institute and Clinic, Department of Psychiatry, Pittsburgh, PA Details: Division of Research
University of Arkansas for Medical Sciences, Department of Psychiatry, Little Rock, AK Details: Instructor and Health Services Research Fellow. Department of
Psychiatry, Centers for Mental Healthcare Research, Center for Rural Health NON-ACADEMIC APPOINTMENTS:
01/2000 - 12/2001 Attending and Teaching 01/2000 - 12/2000 Attending and Teaching CERTIFICATION AND LICENSURE:
Board Certification
Description/Agency
Number Expiration
Acquired
Addiction Psychiatry – American Board of Certified 06/2008 1978 06/2018 Certification
Description/Agency
Number Expiration
Acquired
License to Practice
Description/Agency
Number Expiration
Acquired
Medical License - North Carolina Medical Certified HONORS AND AWARDS:
The Teaching Advancement Program Series: Wake Forest University Teaching Excellence Course: The University of Texas Health Science PROFESSIONAL DEVELOPMENT:
Research
Description
Units/Hours
08/07/2006 - 08/11/2006 Psychiatric Genomics: Applications for Clinical 0.00 / 0.00 Practice, Mayo Clinic. I am using the information gained in current and future NIH applications.
TEACHING
Teaching Roles and Responsibilities in Previous Institutions

Classroom/Laboratory Teaching
Medical Students
Course Title/Clock Hours/
Medicine/
Number of Students
Graduate/
Students
Case presentation of cerebellar ataxia/ 1 ½ 1998-1999 Case Conference on Substance Abuse/ Residents and Fellows
Course Title/Clock Hours/
Medicine/
Number of Students
Residents
and Post-
Residency
2001-2004 Fall & Spring, Child and Adolescent Mock 2003-2004 Research seminar topic: How to read a 2003-2004 Introduction to the Diagnostic Formulation/1 1 hour lecture and 2 sessions to practice Other Disorders of Infancy, Childhood, and Mood Disorders and Suicide in Children and Child and Physiology of withdrawal, tolerance, and Physiology of Cannabis and Hallucinogens/ Family dynamics in families with addictions/ Family-based interventions in families with Endocrinologic Effects of Alcohol, Tobacco, Clinical Teaching
Setting/Role
School: Medicine/
Level: Medical
Student, Resident
and Post-Residency
Role: Attending, Weekly clinical supervisions of Child and Adolescent Psychiatry Fellows Setting: University of Texas Health Science Roles: Attending, supervise PG3 resident on Friday afternoons Setting: the consultation-liaison service at Role: Supervised and taught 4th year psychiatry residents on formulation and management of clients with addictions problems Setting: Adult Dual Diagnosis Unit, Saint Setting: Adult Detoxification Unit, Saint Setting: Psychiatric emergency room, Saint Setting: Inpatient psychiatric unit at Medical RESEARCH
EXPERTISE:
Behavioral phenotypes - To use human laboratory methods to assess behavioral
phenotypes in adolescent substance-abusing populations. Research goals are to
examine: a) impulsivity as a behavioral phenotype to predict abstinence outcomes
(withdrawal severity, lapse to drug use, and relapse); b) relationships among genotypes, environment, impulsivity, and patterns of alcohol, marijuana, and other drug use; and c) how gene-environment interactions confer risk on adolescent substance use disorders. Treatment Research - To develop a treatment research program on medications
as adjuncts to psychosocial treatments for adolescent alcoholism and/or cannabis PUBLICATIONS: ('*' indicates Peer Reviewed)

Published Abstracts
1. Marsh-Richard DM, Dougherty DM, Mathias CW, Dawes MA,
Nouvion SO (2008). Gender comparison of breath-alcohol concentrations following bolus and hourly alcohol dosing procedures using multiple alcohol doses. Alcoholism: Clinical and Experimental Research, in press. 2. Seneviratne, C, Javors MA, Roache JD, Dawes MA, Tiouririne
NA, Johnson BA. Influence of current drinking on the expression of platelet serotonin transporters across allelic variants of 5’-HTTLPR in treatment seeking adult alcoholics, Abstract No. 772. Presented at the RSA Annual Meeting, Santa Barbara, CA; 2005 Jun. 3. Dawes, M.A., Johnson, B.A., Li, M., Ait-Daoud, N. Open-label
study of ondansetron for adolescent alcoholism. Poster for the 50th Anniversary meeting of the American Academy of Child and Adolescent Psychiatry, 2003 4. Dawes, M.A., Tarter, R.E., Kirisci, L., Behavioral self-regulation:
Correlates and 2-year follow-up for boys at risk for substance abuse, Poster for the Annual Meeting of Society for Prevention 5. Dawes, M.A., Family characteristics and boys’ competence as risk
and protective factors associated with juvenile delinquency, Poster for Annual Meeting of American Academy of Child and Adolescent Psychiatry, 1995 6. Dawes, M.A., Relevance of developmental pathways to the
prevention of antisocial behavior, Poster for Fourth Annual National Conference on Prevention Research, 1994 7. Dawes, M.A., Predictors of negative outcomes in residential
treatment for adolescents, Poster presented at the Annual Meeting of American Academy of Child and Adolescent Psychiatry, 1992 Book Reviews
1. Dawes, M.A. Reviewed: Ramussen, N. (in press). On Speed: The
Many Lives of Amphetamine, New England Journal of Medicine Book Chapters
1. Dawes, M.A. Triple-Blind Studies. In: N.J. Salkind (Ed.).
2. Dawes, M.A. True Experimental Designs. In: N.J. Salkind (Ed.).
3. Dawes, M.A. Type III Error. In: N.J. Salkind (Ed.). Encyclopedia
4. Dougherty, D.M., Goldston, D., Dawes, M.A., Mathias, C.W., Richard, D.M. Suicide and Substance Abuse. In: In A. Shrivastava (Ed.). International Handbook on Suicidal Behaviour. London, UK: Gaskell Publications; 2007. 5. Dougherty, D.M., Dawes, M.A., Nouvion, S.O. Changes in
Substance Abuse Behavior. In: S.A. Shumaker, E.B. Schron, J.K. Ockene, & W.L. McBee (Eds.). The Handbook of Health Behavior Change 3rd edition. New York: Springer; 2007. Journal Article
1. Dawes, M.A., Mathias, C.W., Richard, D.M., Hill-Kapturczak, N.,
and Dougherty, D.M. Adolescent Suicidal Behavior and Substance Use: Developmental Mechanisms. Substance Abuse: Research and Treatment, (in press). 2. Dougherty DM, Mathias CW, Richard DM, Furr RM, Nouvion SO, Dawes MA. (in press). Distinctions in Behavioral Impulsivity:
Implications for substance abuse research. Addictive Disorders & Their Treatment, (in press). 3. Dougherty DM, Prevette KN, Mathias CW, Shannon EE, Richard DM, Palmes G, Dawes MA. Impulsivity and clinical symptoms
among adolescents with non-suicidal self-injury with or without attempted suicide. Psychiatry Research, (in press). 4. Dougherty DM, Nouvion SO, Marsh-Richard DM, Dawes MA,
Mathias CW. Familial history of alcoholism and impulsive performance on laboratory behavioral measures. Alcoholism: Clinical and Experimental Research, 2008; 32:207A. 5. Dawes MA, Richard DM, Mathias CW, Dougherty DM.
Prospective Study of Cannabis Withdrawal in Cannabis-Using Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, (2008); 47(9):1095-1096. 6. Johnson, B.A., Javors, M.A., Roache, J.D., Seneviratne, C., Bergeson, S.E., Ait-Daoud, N., Dawes, M.A., Ma, J.Z.: Can
serotonin transporter genotype predict serotonergic function,
chronicity, and severity of drinking? Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008; 32 (1): 209-216. 7. Dougherty DM, Marsh DM, Mathias CW, Dawes MA, Bradley DM,
Morgan CJ, Badawy AA. The effects of alcohol on laboratory- measured impulsivity after L: -Tryptophan depletion or loading. Psychopharmacology (Berl) 2007 Jul;193(1):137-150. 8. Johnson BA, Wells LT, Roache JD, Wallace CL, Ait-Daoud N, Dawes MA, Liu L, Wang XQ, Javors MA. Kinetic and
cardiovascular effects of acute topiramate dosing among non-
treatment-seeking, methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry 2007; Mar;31(2):455-461. 9. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ. Effects of acute topiramate dosing
on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol 2007 Feb;10(1):85-98.
* 10. Dougherty DM, Mathias CW, Liguori A, Marsh DM, Dawes MA,
.Moeller FG. Behavioral impulsivity in adolescents with Conduct Disorder who use Marijuana Addictive Disorders and Their Treatment 2007;6:43-50.
* 11. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL,
Dawes MA, Liu L, Wang XQ. Effects of topiramate on
methamphetamine-induced changes in attentional and perceptual-
motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry 2007 Jan;31(1):123-130.
* 12. Dawes MA, Liguori A, Dougherty DM. Cannabis withdrawal
among adolescent cannabis users in an outpatient research setting American Journal on Addictions 2006;15(6):485-486. * 13. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL,
Dawes MA, Liu L, Wang X-Q. Effects of acute topiramate dosing
on methamphetamine-induced subjective mood. The International Journal of Neuropsychopharmacology 2007; 10 (1): 85-98.
* 14. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wells, L.T., Wallace,
C.L., Dawes, M.A., Liu, L., Wang, X.-Q.: Effects of topiramate on
methamphetamine-induced changes in attentional and perceptual-
motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007; 31 (1): 123-130.
* 15. Johnson, BA, Dawes MA, Roache JD, Wells LT, Ait-Daoud N,
Mauldin JB, Wang Y, Lancaster JL, Fox, PT. Acute intravenous low- and high-dose cocaine administration reduces global and regional cerebral blood flow in recently abstinent cocaine use disorder subjects Journal of Cerebral Blood Flow & Metabolism 2005;25(7):928-936.
* 16. Dawes MA, Johnson BA, Ait-Daoud N, Ma JZ, Cornelius JR. A
prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 2005;30(6):1077-1085.
* 17. Johnson BA, Roache JD, Tiouririne NA, Wallace CL, Wells LT,
Dawes MA, Wang, Y. Effects of isradipine on cocaine-induced
changes in cognitive performance in recently abstinent cocaine-
dependent individuals. International Journal of Neuropsychopharmacology 2005;8(4):549-556. * 18. Johnson BA, Roache JD, Tiouririne NA, Wallace CL, Wells LT,
Dawes MA, Wang,Y. Effects of isradipine, a dihydropyridine-class
calcium channel antagonist, on d-methamphetamine‘s subjective and reinforcing effects. International Journal of Neuropsychopharmacology 2005;8(2):203-213.
* 19. Dawes MA, Johnson BA, Ma JZ, Ait-Daoud N, Thomas SE,
Cornelius JR. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence Addictive Behaviors 2005;30:1630-1637.
* 20. Dawes MA, Johnson BA. Pharmacotherapeutic trials in adolescent
alcohol use disorders: opportunities and challenges. Alcohol and Alcoholism 2004;39(3):1-12.
* 21, Dawes MA. Pharmacological Interventions for Adolescents with
Alcohol Use Disorders The Brown University Child and Adolescent Psychopharmacology Update 2004;6(9):1-7. * 22. Dawes MA, Antelman SM, Vanyukov MM, Giancola P, Tarter RE,
Susman EJ, Mezzich A, Clark DB. Developmental sources of variation in liability to adolescent substance use disorders. Drug Alcohol Depend 2000;61(1):3-14. * 23. Ammerman RT, Kolko DJ, Kirisci L, Blackson TC, Dawes MA.
Child abuse potential in parents with histories of substance use disorder. Child Abuse Negl 1999;23(12):1225-1238.
* 24. Dawes MA, Dorn LD, Moss HB, Yao JK, Kirisci L, Ammerman RT,
Tarter RE. Hormonal and behavioral homeostasis in boys at risk for substance abuse. Drug Alcohol Depend 1999;55:165-176. * 25. Tarter, RE, Vanykov, MM, Giancola, P, Dawes M, Blackson, T.
Etiology of early age onset substance use disorder: A maturational perspective Development and Psychopathology 1999;11:657-683. * 26. Dawes M, Moss, H, Clark, D, Kirisci, L, Tarter, RE. Family and
peer correlates of behavioral self-regulation in boys at risk for substance abuse American Journal Drug Alcohol Abuse 1999;25(2):219-237.
* 27. Dawes MA, Tarter RE, Kirisci L. Behavioral self-regulation:
correlates and 2 year follow-ups for boys at risk for substance abuse. Drug and Alcohol Dependence 1997;45(3):165-176.
* 28. Harper, G, Dawes M, Azlin, C, Fishman, S. Partial small bowel
obstruction in a child on an antipsychotic. Journal of Child and Adolescent Psychopharmacology 1995;5(1):81-84.
* 29. Wherry, JD, Dawes M, Rost, K, Smith, GR, Jolley, J. Criterion-
related validity of the Child Behavior Checklist by staff in residential treatment settings. Residential Treatment for Children and Youth 1993;10:35-45.
* 20. Mabe, PA, Dawes, M.A. When a child dies:The impact of being a
Christian Journal of Psychology and Theology 1991;19:334-343. * 31. Dawes MA, Frank S, Rost K. Clinician assessment of psychiatric
comorbidity and alcoholism severity in adult alcoholic inpatients. Am J Drug Alcohol Abuse 1993;19(3):372-386.
PRESENTATIONS:
John, S., Richard, D.M., Mathias, C.W., Dawes, M.A., Dougherty, D.M.
(2009, April). Factors of Cigarette and Alcohol Use in Adults Aged 21-45.
Poster presented at the 55th annual meeting of the Southwestern
Psychological Association, San Antonio, TX.
Surber, A.E., Richard, D.M., Mathias, C.W., Dawes, M.A., Douherty, D.M.
(2009, April). Beliefs and Expectations about Alcohol are related to Level
of Education. Poster presented at the 55th annual meeting of the
Southwestern Psychological Association, San Antonio, TX.
Kilpatrick, A.C., Dawes, M.A., Mathias, C.W., Richard, D.M., and
Dougherty, D.M. (2009, April). Multiple methods to assess abstinence
outcomes in marijuana-using adolescents. Poster presented at the 55th
annual meeting of the Southwestern Psychological Association, San
Antonio, TX.
Cates, S. Mathias, C. W., Farris, S., Richard, D. M., Dawes, M. A., and
Dougherty, D. M. (2009, April). Training "experts" in consensus ratings of
the Stressful Life Events Schedule. Poster presented at the 55th annual
meeting of the Southwestern Psychological Association, San Antonio, TX.
Farris, S., Mathias, C. W., Cates, S., Dawes, M. A., Richard, D. M., and
Dougherty, D. M. (2009, April). Lifetime history of stressful life events in
an adolescent inpatient psychiatric sample. Poster presented at the 55th
annual meeting of the Southwestern Psychological Association, San
Antonio, TX.
John, S., Richard, D.M., Mathias, C.W., Dawes, M.A., and Dougherty,
D.M. (2009, April). Predictive Factors of Cigarette and Alcohol Use in
Adults Aged 21-45. Poster presented at the 55th annual meeting of the
Southwestern Psychological Association, San Antonio, TX.
Surber, A., Richard, D.M., Mathias, C.W., Dawes, M.A., and Dougherty,
D.M. (2009, April). Beliefs and Expectations about Alcohol are related to
Level of Education. Poster presented at the 55th annual meeting of the
Southwestern Psychological Association, San Antonio, TX.
Dougherty, D. M., Richard, D. M., Mathias, C. W., Hill-Kapturczak, N., Dawes,
M. A., and Badawy, A. A.-B. (2008, October). L-tryptophan as a research
compound and therapeutic agent. Presented in a symposium entitled: Clinical studies with agents of different pharmacological activity. Symposia conducted at the 2nd World Conference on Magic Bullets (Ehrlich II), celebrating the 100th anniversary of the Nobel Prize Award to Paul Ehrlich, Nürnberg, Germany. Dawes, M.A. (2008, April). Impulsivity and Abstinence Outcomes in
Cannabis-Using Adolescents. Invited speaker at the Clinical Research Faculty Meeting, a monthly meeting in the Department of Psychiatry, the University of Texas Health Science Center at San Antonio, San Antonio, TX Dawes, M.A. (2008, April) Impulsivity and Abstinence Outcomes in Cannabis-
Using Adolescents. Invited speaker at the Addictions Seminar, a monthly seminar at the University of Texas Health Science Center at San Antonio, Dawes, M.A. (2008, March). Selected articles and organized format for 4-
week seminar on the Antecedents and Consequences of Cannabis use in
Humans, for the Behavioral Psychopharmacology Tuesday Seminar. The 4
readings were selected to provide an overview of the antecedents (e.g.,
cognitive risk factors) and consequences (e.g, cognitive and behavioral
effects) of marijuana use in humans. The first week I presented:
Giancola PR, Moss HB, Martin CS, Kirisci L, Tarter RE. (1996). Executive cognitive functioning predicts reactive aggression in boys at high risk for substance abuse: A prospective study. Alcoholism: Clinical and Experimental Research, 20, 740-744. Dougherty, D.M., Nouvion, S.O., Marsh-Richard, D.M., and Dawes, M.A.,
Mathias CW ( 2008, February). Familial history of alcoholism and impulsive performance on laboratory behavioral measures. Poster presented at the annual meeting of the Texas Research Society on Alcoholism, Austin, Texas. Marsh-Richard DM, Dougherty DM, Mathias CW, Dawes MA, Nouvion SO
(2008, February). Gender comparison of breath-alcohol concentrations
following bolus and hourly alcohol dosing procedures using multiple alcohol doses. Poster presented at the annual meeting of the Texas Research Society on Alcoholism, Austin, Texas Dawes, MA (February, 2008) Introduction to Adolescent Alcohol and Other
Substance Abuse Curriculum
Details: Invited speaker for videotaped lecture, as a part of a comprehensive
curriculum on assessment and treatment of Adolescent Alcohol and Other Substance Abuse; Sponsor: The American Academy of Child and Adolescent Psychiatry, Pittsburgh, PA Dawes, MA (September, 2007) Assessment and Treatment of Adolescent
Substance Use Disorders, North Carolina Psychiatric Association, Wrightsville Beach, NC (Invited Speaker) Dawes, MA (January, 2007) Assessment and Treatment of Adolescent
Substance Use Disorders, Social Workers and Nurses, Winston-Salem Forsyth County Schools, Winston-Salem, NC (Sole Presenter) Dawes, MA (January, 2006) Assessment and Treatment of Adolescent
Substance Use Disorders, Grand Rounds, Departments of Child and
Adolescent Psychiatry and Psychiatry, University of Cincinnati, Cincinnati, OH (Invited Speaker) Dawes MA, Johnson BA, Ait-Daoud N (January, 2003) Open-label study of
ondansetron for adolescent alcoholism, 30th Anniversary Meeting, American Academy of Child and Adolescent Psychiatry (Co-Presenter) Details: Poster Presentation
Dawes, MA (January, 2003) Spotting Substance Abusers, Continuing
Education, Dental Hygienists, University of Texas Health Science Center at San Antonio, San Antonio, TX (Invited Speaker) Dawes, MA (January, 2001) Assessment and Treatment of Adolescent
Substance Use Disorders, Grand Rounds, Department of Psychiatry,
University of Texas Health Science Center at San Antonio, San Antonio, TX (Invited Speaker) Dawes, MA (January, 2000). Adolescent Substance Use Disorders,
Substance Abuse Training for Law Enforcement, Tapatio Springs, TX (Sole Presenter) Dawes, MA (January, 1999) Drug Use Liability During Pubertal
Development, Grand Rounds, Division of Child and Adolescent Psychiatry, University of Washington, Seattle, WA (Invited Speaker) Dawes, MA (January, 1999) Developmental Sources of Variation in Liability
to Adolescent Substance Use Disorders, University of Texas Health Science Center, Houston, TX (Invited Speaker) Dawes, MA (January, 1998) Etiology of Adolescent Substance Abuse,
Annual Medical-Scientific Conference, American Society of Addiction Medicine (Invited Speaker) Dawes, MA (January, 1998) Drug Use Liability During Pubertal
Development, Adult Psychiatry Residents, St. Francis Medical Center (Invited Speaker) Dawes, MA, Tarter, RE, Kirisci L (January, 1997) Behavioral self-regulation:
Correlates and 2-year follow-up for boys at risk for substance abuse, Annual Meeting, Society for Prevention Research (Co-Presenter) Details: Tarter RE, Kirisci L; Poster Presentation
Dawes, MA (January, 1997) Etiology of Adolescent Substance Abuse, Annual
Meeting, Adolescent Substance Abuse: From Neurobiology to Assessment and Treatment, Canadian and American Academies of Child and Adolescent Psychiatry (Invited Speaker) Dawes, MA (January, 1997) Drug Use Liability During Pubertal
Development, Department of Biobehavioral Health, Penn State University (Invited Speaker) Dawes, MA (January, 1996) Drug Use Liability During Pubertal
Development, Annual Research Presentation, NIMH Child Clinical Research Training Fellowship (Sole Presenter) Dawes, MA (January, 1995) Family characteristics and boys' competence as
risk and protective factors associated with juvenile delinquency, Annual
Meeting, American Academy of Child and Adolescent Psychiatry (Sole Presenter) Details: Poster Presentation
Dawes, MA (May, 1995) Risk and protective effects of family characteristics,
child-rearing practices, and high and low levels of boys‘ competencies
predicting delinquency seriousness in school-aged boys, Annual Research Presentation, NIMH Child Clinical Research Training Fellowship (Sole Presenter) Dawes MA (Fall, 1994) Relevance of developmental pathways to the
prevention of antisocial behavior, Fourth Annual National Conference, Prevention Research (Sole Presenter) Details: Poster Presentation
Dawes, MA (October, 1994) Resilient youth: Caretaker‘s psychopathology
and substance misuse and their children‘s competencies, Annual Meeting,
Eli Lilly Pilot Research Committee, American Academy of Child and Adolescent Psychiatry (Sole Presenter) Dawes, MA (October 1992) Predictors of negative outcomes in residential
treatment for adolescents, Annual Meeting, American Academy of Child and Adolescent Psychiatry (Sole Presenter) Details: Poster Presentation
Dawes, MA (January, 1992) Clinician assessment of psychiatric comorbidity
and alcoholism severity in adult alcoholic inpatients, Southern Association for Research in Psychiatry (Sole Presenter) Dawes, MA (Fall, 1991) Diagnostic concordance in somatization disorder: A
comparison with DSM-IV criteria, Southern Association for Research in
RESEARCH GRANTS:
Federal
Project #: R-21 DA022711
Funding Agency: National Institute on Drug Abuse
Title: Impulsivity and abstinence outcomes in cannabis-using adolescents
Status: Active
Period: 01/01/2008 - 12-31-2009
Role: Principal Investigator
% Effort: 20
Total Costs: $398,619.00
Project #: R01-MH-077684
Funding Agency: National Institute of Mental Health
Title: Impulsivity and Biological Markers for Suicidality and Drug Use in Adolescents
Status: Active
Period: 04/2007 - 03/2012
Role: Co-Investigator
% Effort: 15
Total Costs: $3,181,508.00
Grant Detail:
Project: CPP-01004
Funding: Catalyst Pharmaceutical Partners, Inc.
Title: Vigabitrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Active % Effort: 20
Period:
Role: Research Psychiatrist
Total Costs:
Grant Detail:

Project #: NO10DA98101
Funding Agency: National Institute on Drug Abuse
Title: Phase II, Double-Blind, Placebo-Controlled Trial of Modafinil for the Treatment
Status: Complete
Period: 10/2003 - 08/2005
Role: Co-Investigator
% Effort: 10
Total Costs: $856,024.00
Grant Detail:
Project #:
Funding Agency: NIH/NIDA
Title: Phase I Interaction Clinical Trial with Disulfiram, Cocaine, and Alcohol
Status: Complete
Period: 10/2003 - 10/2004
Role: Co-Investigator
% Effort: 10
Total Costs: $513,470.00
Grant Detail:
Project #: 5R21AA013435-02
Funding Agency: NIH/NIAAA
Title: Clinical-Genetic Variation in GABA/Alcohol Sensitivity
Status: Complete
Period: 07/2002 - 08/2005
Role: Co-Investigator
% Effort: 5
Total Costs: $405,309.00
Grant Detail:
Project #: R01DA11227-01
Funding Agency: NIH / NIDA
Title: Cocaine Brain Effects and Neuroimaging
Status: Complete
Period: 02/1999 - 01/2003
Role: Co-Investigator
% Effort: 20
Total Costs: $1,091,289.00
Grant Detail: My responsibilities included running the protocol during Positron
Emission Tomography imaging days, writing revised pharmacy protocols and writing Project #: K08 DA0029901A1
Funding Agency:
Title: Drug Use Liability During Pubertal Development
Status: Complete
Period: 07/1997 - 06/2002
Role: Principal Investigator
% Effort: 75
Total Costs: $325,000.00
Grant Detail:
Project #: DA056050
Funding Agency: National Institute on Drug Abuse
Title: Drug Abuse Vulnerability: Mechanisms and Manifestations
Status: Complete
Period: 01/1996 - 12/1999
Role: Co-Investigator
% Effort: 20
Total Costs:
Grant Detail:
Project #: NIMH T-32
Funding Agency: National Institute of Alcohol Abuse and Alcoholism
Title: Post-Doctoral Research Fellowship
Status: Complete
Period: 07/1994 - 06/1996
Role: Co-Investigator
% Effort: 100
Total Costs:
Grant Detail:
Project #:
Funding Agency: National Institute on Drug Abuse
Title: Impulsivity and Antecedents to Adolescent Marijuana Use
Status: Pending
Period:
Role: Co-Principal Investigator
% Effort: 30
Total Costs: $1,797,896.00
Grant Detail: To be resubmitted, June 2008
Project #:
Funding Agency: National Institute of Mental Health
Title: Impulsivity and Stimulant Response in Early- and Late-Onset CD with
Comorbid ADHD
Status: Pending
Period:
Role: Co-Investigator
% Effort: 15
Total Costs: $1,746,858.00
Grant Detail:
Project #: R-01
Funding Agency: National Institute of Alcohol Abuse and Alcoholism
Title: Alcohol Binging: Disruptions in Impulse Control and 5-HT as Underlying
Mechanisms
Status: Pending
Period:
Role: Co-Investigator
% Effort: 15
Total Costs: $789,250.00
Grant Detail:
Private
Project #:
Funding Agency: SFY 07 Mental Health Trust Fund (MHTF)
Title: Initiative A: Child and Adolescent Substance Abuse or Child and Adolescent
Mental Health Treatment and Co-Occurring MH/SA Disorders Initiative Status: Active
Period: 07/2007 - 07/2008
Role: Co-Investigator
% Effort: 20
Total Costs: $232,954.00
Grant Detail: Award of one-time non-recurring funds for Mental Health and
Substance Abuse Services Contracted provider Pilot Projects. Helped write portions
of the grant application on psychiatric assessment and treatment, and helped develop a psychiatric dual-diagnosis clinic for PG2 child/adolescent psychiatry fellows, Summer, 2007 – September, 2007 Project #:
Funding Agency: Friends of Psychiatry and Executive Research (ERC)
Title: Serotonin Dysregulation in Adolescents with Alcohol Problems
Status: Complete
Period: 06/2002 - 08/2005
Role: Co-Investigator
% Effort: NA
Total Costs: $15,000.00
Grant Detail: Pilot funds
Project #:
Funding Agency: Goldsbury Foundation
Title: Making a Difference in Alcohol Alcoholism Prevention and Treatment,
Substudy: Open-Label Study of Ondansetron for Adolescent Alcoholism
Status: Complete
Period: 07/2001 - 06/2003
Role: Co-Investigator
% Effort: NA
Total Costs: $56,000.00
Grant Detail:
Project #:
Funding Agency: Eli Lilly
Title: Resilient youth: Caretaker‘s psychopathology and substance misuse, and their
children‘s competencies
Status: Complete
Period: Awarded - 01/1994 - 12/1994
Role: Principal Investigator
% Effort: NA
Total Costs: $5,000.00
Grant Detail:
ADMINISTRATIVE RESPONSIBILITIES:
Description
General Clinical Research Laboratory and Clinic (UTHSCSA) Includes training of research staff to use various instruments Supervision of physician’s assistant (PA), review of medical status of research participants, coordination of referrals for research participants who want clinical follow-up; supervision of data collectors for my research protocols. OTHER SERVICE:
Description
Administration Graduate Chapter of Inter- University of North Carolina at Chapel Hill, NC PATIENT CARE:
Description
11/2008-Present Outpatient Center for Health Care 07/2004-09/2007 Outpatient Attending, Adolescent Dual 08/2005-09/2007 Outpatient Attending, Child and Adolescent Clinic, Wake Forest University Health Sciences Psychiatric evaluations for prospective liver transplant patients, San Antonio, TX Psychiatric and Substance Abuse Evaluations and Consultations Outpatient assessment and treatment of child and adolescent psychiatric SERVICE TO THE INSTITUTION:
Description
Department of Psychiatry and Behavioral Medicine, Wake Forest University Teaching Coordinator, Department of Psychiatry, The University of Texas Health SERVICE TO THE PROFESSION:
Description
Alcohol and Other Substance Abuse Curriculum Invited speaker for introductory lecture to the Adolescent Alcohol and Other Stubstance Abuse Curriculum; Learning Objectives: Describe epidemiology and problems associated with diagnosing adolescent substance use disorders; Identify similarities and differences between adolescents and adults with substance use disorders, recognized developmental patterns relevant to the assessment of adolescents with substance use disorders. Sponsor: American Academy of Child and Adolescent Psychiatry In 2006, coordinated collaborations of the NRLC faculty with David Goldman, M.D., Chief and his colleagues at the Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism. Dr. Goldman is a consultant in the area of his expertise in our group‘s funded R-01, "Impulsivity and Biological Markers for Suicidality and Drug Use in Adolescents." (RFA-NH-04-003) for Centers on Intervention for Prevention of Suicide, supported by the National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute of Mental Health (NIMH) Substance Abuse and Mental Health Services Administration; Effective Adolescent Treatment, T103-07; SRA: Jerry Dawson, G14 Academy of Child and Adolescent Psychiatry SERVICE TO THE PUBLIC:
Description
This clinic is supported in part by: Initiative A: Child and Adolescent Substance Abuse or Child and Adolescent Mental Health Treatment and Co-Occurring MH/SA Disorders Initiative (Child/Adolescent)", LME Application for FY 07 Mental Health Trust and Substance Abuse Services Contracted Provider Pilot Projects. Services provided will include psychiatric assessment, medication management, supervision of family therapists, and supervision of 2nd year child and adolescent fellows Community Briefing, National Youth Anti-Drug Media Campaign, San Antonio, Voice of Calvary Ministries, Jackson, MI PROFESSIONAL AFFILIATIONS:
Organization
International Society for Tryptophan Research Additional Details: Committee Memberships: NCPA Program Committee
and Addiction Committee; Presenting at Annual meeting, September, 2007 American Academy of Addiction Psychiatry American Academy of Child & Adolescent Psychiatry Christian Medical and Dental Association COMMITTEES (OTHER):
DEPARTMENT
Committee
01/2006-09/2007 Research Committee, Wake Forest University Health Sciences, Department of Psychiatry and 01/2006-09/2007 Child and Adolescent Psychiatry Educational Policy Committee (EPC), Wake Forest University Health Sciences, Department of Psychiatry and Behavioral Medicine 01/2000-12/2001 Biostatistics Committee, The University of Texas Health Science Center at San Antonio, Medical

Source: http://www.nrlc-group.net/pdf/DawesCV12-09-08.pdf

www1.vdbd.de

Metformin in Pregnancy – Is it safe? Does it work? Cellular and Metabolic Actions of Metformin – Applications to ist use During Pregnancy (Clifford J. Bailey, Birmingham) Der Einführungsvortrag dieses überaus spannenden Symposiums verschaffte den Teilnehmern einen sehr eingehenden Überblick über das Metformin. Der Redner bestätigte, dass es sich bei Metformin um das weltweit am m

tellijavastutus.ee

Instructions for the Luotettava Kumppani Estonia Programme The Luotettava Kumppani Programme Estonia concerns solely Estonian companies. Accession to the program-me requires the signing and returning of the Power of Attorney Agreement enclosed below. Under this agreement Suomen Tilaajavastuu Oy will retrieve and publish all information required under the Fin-nish Act on the Contra

© 2010-2018 Modern Medicine